SAT0093 Association of Alcohol Consumption with Disease Activity in Patients with Rheumatoid Arthritis Using the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort. (9th June 2015)

• Record Type: Journal Article
• Authors: Shimizu, Y.; Shidara, K.; Tanaka, E.; Inoue, E.; Yamaguchi, R.; Sugimoto, N.; Hoshi, D.; Nakajima, A.; Momohara, S.; Taniguchi, A.; Yamanaka, H.
• Is Part Of: Annals of the rheumatic diseases. Volume 74(2015)Supplement 2
• Page Start: 682
• Page End: 683
• Publication Date: 2015-06-09
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2015-eular.2639
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: While the results of several observational studies suggest that light-to-moderate alcohol consumption may decrease the risk for susceptibility to or severity of rheumatoid arthritis (RA) (1-3), the findings regarding alcohol's effect on RA disease activity have been inconsistent. Although alcohol consumption in the Japanese general population was lower than that in European countries according to the 2011 World Health Organization's Global Status Report on Alcohol and Health, there are few reports on alcohol consumption in Japanese RA patients. Objectives: To examine the relationship between alcohol consumption and disease activity in RA patients using the large observational cohort, IORRA. Methods: Subjects were RA patients who participated in the IORRA study for the first time between October 2007 and October 2012. Patients were divided into 6 groups by alcohol-drinking status at baseline: the non-drinking group, the past-drinking group, drinking group 1 (0 g < amount of drinking per day [Alco-drink] 14 g), drinking group 2 (14 g < Alco-drink 28 g), drinking group 3 (28 g < Alco-drink 50 g), and drinking group 4 (50 g < Alco-drink). Multiple regression analyses were used to examine the relationship between alcohol consumption and baseline DAS28 or change in DAS28 from baseline to 1 year. Results: Data from 2, 369 patients (female: 83.6%, mean age: 54.6 years old, mean disease duration: 5.6 years, and mean DAS28: 3.5) were analyzed. The number of patients and their characteristics (% female, mean age, mean disease duration, mean DAS28 at baseline/after 1 year) in the non-drinking group, the past-drinking group, and drinking groups 1, 2, 3, and 4 were 1, 436 (90.5%, 55.6 years old, 6.0 years, 3.6/2.9), 294 (83.3%, 53.7 years old, 4.7 years, 3.9/2.8), 263 (79.5%, 50.6 years old, 5.6 years, 3.3/2.6), 124 (66.1%, 53.6 years old, 3.6 years, 3.2/2.5), 111 (58.6%, 57.4 years old, 5.0 years, 3.4/2.8), and 114 (49.1%, 51.4 years old, 4.5 years, 3.3/2.6), respectively. Multivariate regression analysis confirmed that the baseline DAS28 in the past-drinking group (p<0.001) was significantly higher than that in the non-drinking group after adjusting for age, gender, RA disease duration and body mass index (BMI), whereas the baseline DAS28 in drinking group 1 (p=0.04) and group 2 (p=0.01) was significantly lower than that in the non-drinking group after adjusting for the same variables. There was no association between alcohol-drinking status and the change in DAS28 from baseline to 1 year after adjusting for age, gender, RA disease duration, BMI and DAS28 at baseline. Conclusions: Although light alcohol consumption was associated with lower baseline DAS28 in RA patients, alcohol-drinking status was not associated with response to RA treatment. References: Di Giuseppe D. BMJ, 2012 Jul 10;345:e4230. Kallberg H. Ann Rheum Dis, 2009;68:222-7. Maxwell JR. Rheumatology (Oxford), 2010;49:2140-6. Disclosure of Interest: Y. Shimizu: None declared, K. Shidara: None declared, E. Tanaka: None declared, E. Inoue: None declared, R. Yamaguchi: None declared, N. Sugimoto: None declared, D. Hoshi: None declared, A. Nakajima: None declared, S. Momohara Consultant for: AbbVie, Bristol-Myers-Squibb, Eisai, Mitsubishi-Tanabe, and Takeda., A. Taniguchi Grant/research support from: Takeda., Consultant for: AbbVie, Eisai, Mitsubishi-Tanabe, and Teijin., H. Yamanaka Grant/research support from: AbbVie, Asahikasei Pharma, Astellas, Bristol-Myers-Squibb, Chugai, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Janssen, Mitsubishi-Tanabe, MSD, Nippon Kayaku, Pfizer, Santen, Taisho-Toyama, Takeda, Teijin Pharma., Consultant for: Teijin Pharma, Chugai, Astellas, Bristol-Meyers, AbbVie, Daiichi-Sankyo, Nihon-Kayaku, Mitsubishi-Tanabe, Pfizer, Takeda, UCB.